Photo of Paolo Tarantino from X
Feb 10, 2024, 08:06
Paolo Tarantino: Final OS from BROCADE3 phase 3 trial
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“Final OS from BROCADE3 phase 3 trial: adding veliparib to 1L carbo-taxol did not improve OS in BRCA-mutant patients with advanced TNBC. Notably, mPFS (>12 months) and mOS (≃30 months) were longer than expected. Effect of the carbo-taxol combo, or chance?”
Visit the article website.
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19